Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -3585.62% is 15349% below its 5-year average of -23.21%, around the middle of its 5-year range (-10952.10%–5.13%).
4.25% below its 12-month average of -3439.39%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5118.78%.
NET PROFIT MARGIN
-3585.62%
NET PROFIT MARGIN AVG TTM
-3439.39%
NET PROFIT MARGIN AVG 3Y
0.00%
NET PROFIT MARGIN AVG 5Y
-23.21%
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-4.25%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
-15348.92%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.35%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-1024362.86%
vs the sector median at left
Milestone Pharmaceuticals Inc.
Market Cap
$95.14M
Net Profit Margin
-3585.62%
TTM Avg
-3439.39%
3Y Avg
0.00%
5Y Avg
-23.21%
Market Cap
$97.14M
Net Profit Margin
-4477.08%
TTM Avg
-2757.42%
3Y Avg
-1378.71%
5Y Avg
-931.09%
Market Cap
$92.69M
Net Profit Margin
-1.41%
TTM Avg
0.88%
3Y Avg
1.31%
5Y Avg
1.31%
Market Cap
$99.62M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$90.64M
Net Profit Margin
7051.24%
TTM Avg
-5065.26%
3Y Avg
-2532.63%
5Y Avg
-1688.42%
Market Cap
$90.37M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$90.20M
Net Profit Margin
2.57%
TTM Avg
-5.95%
3Y Avg
-14.59%
5Y Avg
-10.91%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Milestone Pharmaceuticals Inc. (MIST) | $95.14M | -3585.62% | -3439.39% | 0.00% | -23.21% |
| Korro Bio, Inc. (KRRO)vs › | $97.14M | -4477.08% | -2757.42% | -1378.71% | -931.09% |
| Park Dental Partners, Inc. Common Stock (PARK)vs › | $92.69M | -1.41% | 0.88% | 1.31% | 1.31% |
| PolyPid Ltd. (PYPD)vs › | $97.90M | 0.00% | 0.00% | 0.00% | 0.00% |
| Conexeu Sciences Inc. (CNXU)vs › | $97.94M | N/A | N/A | N/A | N/A |
| OnKure Therapeutics, Inc. (OKUR)vs › | $99.62M | 0.00% | 0.00% | 0.00% | 0.00% |
| Rallybio Corporation (RLYB)vs › | $90.64M | 7051.24% | -5065.26% | -2532.63% | -1688.42% |
| Biomea Fusion, Inc. (BMEA)vs › | $90.37M | 0.00% | 0.00% | 0.00% | 0.00% |
| ImmuCell Corporation (ICCC)vs › | $90.20M | 2.57% | -5.95% | -14.59% | -10.91% |
| Equillium, Inc. (EQ)vs › | $89.78M | 0.00% | -9.81% | -113.18% | -75.45% |
Operating Margin
-4041.7%
Net Profit Margin
-3585.6%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | -5118.78% |
| 2026-03-31 | -10952.10% |
| 2025-12-31 | -1126.07% |
| 2025-09-30 | 0.00% |
| 2025-06-30 | 0.00% |
| 2025-03-31 | 0.00% |
| 2024-12-31 | 0.00% |
| 2024-09-30 | 0.00% |
| 2024-06-30 | 0.00% |
| 2024-03-31 | 0.00% |
| 2023-12-31 | 0.00% |
| 2023-09-30 | 0.00% |
| 2023-06-30 | 0.00% |
| 2023-03-31 | -1495.00% |
| 2022-12-31 | -376.49% |
| 2022-09-30 | -970.40% |
| 2022-06-30 | 0.00% |
| 2022-03-31 | 0.00% |
| 2021-12-31 | 0.00% |
| 2021-09-30 | 0.00% |
| 2021-06-30 | 5.13% |
| 2021-03-31 | 0.00% |
| 2020-12-31 | 0.00% |
| 2020-09-30 | 0.00% |
| 2020-06-30 | 0.00% |
| 2020-03-31 | 0.00% |
| 2019-12-31 | 0.00% |
| 2019-09-30 | 0.00% |
| 2019-06-30 | 0.00% |
| 2019-03-31 | 0.00% |
| 2018-12-31 | 0.00% |
| 2018-09-30 | 0.00% |
| 2018-06-30 | 0.00% |
| 2018-03-31 | 0.00% |
